4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner [Yahoo! Finance]
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Yahoo! Finance
Tetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals, appointed as Venture Partner London, United Kingdom, 30 March 2026 - 4BIO Capital, a specialist biotech venture firm transforming innovative technologies into breakthrough precision therapies, today announces the appointments of Dr. Therese (Thera) Liechtenstein as Partner and Dr. Tetsuyuki (Tetsu) Maruyama as Venture Partner. Thera steps into the role of Partner having served as Investment Director at 4BIO Capital since 2024, where she held board roles at Actithera, Araris Biotech and Code Biotherapeutics. During her tenure as Investment Director, she led Actithera's oversubscribed $75.5 million Series A financing and supported Araris Biotech's acquisition by Taiho Pharmaceutical for up to $1.14 billion. Thera joined 4BIO Capital from M Ventures, the corporate venture arm of Merck KGaA, where she was Senior Investment Director in the Biotechnology team. At M Ventures, she led company creation efforts, new
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- AI in Pharmacovigilance Course: Comprehensive Introduction to the Transformative Impact of Artificial Intelligence on Drug Safety and Monitoring (ONLINE EVENT: May 18, 2026) [Yahoo! Finance]Yahoo! Finance
- Takeda Pharmaceutical (TAK) was upgraded by Sanford C. Bernstein from "market perform" to "outperform".MarketBeat
- Takeda (TAK) Receives FDA Priority Review for Rusfertide in PV Treatment [Yahoo! Finance]Yahoo! Finance
- Major biopharmaceutical company to lay off nearly 250 workers in MA [Yahoo! Finance]Yahoo! Finance
- DIA's LIFT Series Brings Startup Pitch Competitions, Innovation Programming to Global Annual Meeting [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- 4/6/26 - Form 3
- TAK's page on the SEC website